H.R. 5725House115th Congress (2017-2019)In Committee

BEST Act

Introduced May 9, 2018

AI-Generated Summary

Updated April 15, 2026 at 9:48 PM UTC

The BEST Act directs the Secretary of Health and Human Services to prepare a report for Congress on how Medicare Advantage (MA) plans include supplemental benefits that treat or prevent substance‑use disorders. The report must be delivered within two years of the law’s enactment and will look at the availability of such benefits for people enrolled in MA plans, including those with special‑needs or Medicaid eligibility.

Key Provisions

  • The Secretary must submit a report to Congress no later than two years after the Act’s passage.
  • The report must be developed after consulting beneficiaries, advocacy groups, MA plan sponsors, pharmacy benefit managers, and health‑care providers.
  • It must analyze how many MA plans offer supplemental benefits such as medication‑assisted treatment for opioid use, counseling, peer‑recovery services, and non‑opioid pain alternatives.
  • The report must identify challenges to offering these benefits and assess how changes to the Medicare Advantage rebate rate could affect their availability.
  • It must include recommendations for improving coverage or incentivizing plans to add more substance‑use‑disorder related supplemental benefits.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions
HouseCommittee Latest Action

Referred to the Subcommittee on Health.

May 23, 2018

View full timeline
HouseIntro Referral

Introduced in House

May 9, 2018

HouseIntro Referral

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

May 9, 2018

HouseCommittee

Referred to the Subcommittee on Health.

May 23, 2018

Floor Debate

2 members

What members said about H.R. 5725 on the floor

1 Republican1 Democrat
Judy Chu
Rep. Judy ChuD-CA-27 · Jun 19, 2018

Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, according to the Centers for Disease Control and Prevention, more than 42,000 Americans died from opioid-related drug overdoses in…

Jackie Walorski
Rep. Jackie WalorskiR-IN-2 · Jun 19, 2018

Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 6110) to amend title XVIII of the Social Security Act to provide for the review and adjustment of payments under the Medicare…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued May 9, 2018

I

115th CONGRESS

2d Session

H. R. 5725

IN THE HOUSE OF REPRESENTATIVES

May 9, 2018

Mr. Roskam (for himself, Ms. Sánchez, Mr. Shimkus, and Mr. Ruiz) introduced the following bill; which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To direct the Secretary of Health and Human Services to submit to Congress a report on the extent to which Medicare Advantage plans offered under part C of the Medicare program include supplemental health care benefits designed to treat or prevent substance use disorders.

1.

Short title

This Act may be cited as the Benefit Evaluation of Safe Treatment Act of 2018 or the BEST Act of 2018.

2.

Studying the availability of supplemental benefits designed to treat or prevent substance use disorders under Medicare Advantage plans

(a)

In general

Not later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the Secretary) shall submit to Congress a report on the availability of supplemental health care benefits (as described in section 1852(a)(3)(A) of the Social Security Act (42 U.S.C. 1395w–22(a)(3)(A))) designed to treat or prevent substance use disorders under Medicare Advantage plans offered under part C of title XVIII of such Act. Such report shall include the analysis described in subsection (c) and any differences in the availability of such benefits under specialized MA plans for special needs individuals (as defined in section 1859(b)(6) of such Act (42 U.S.C. 1395w–28(b)(6))) offered to individuals entitled to medical assistance under title XIX of such Act and other such Medicare Advantage plans.

(b)

Consultation

The Secretary shall develop the report described in subsection (a) in consultation with relevant stakeholders, including—

(1)

individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act;

(2)

entities who advocate on behalf of such individuals;

(3)

Medicare Advantage organizations;

(4)

pharmacy benefit managers; and

(5)

providers of services and suppliers (as such terms are defined in section 1861 of such Act (42 U.S.C. 1395x)).

(c)

Contents

The report described in subsection (a) shall include an analysis on the following:

(1)

The extent to which plans described in such subsection offer supplemental health care benefits relating to coverage of—

(A)

medication-assisted treatments for opioid use, substance use disorder counseling, peer recovery support services, or other forms of substance use disorder treatments (whether furnished in an inpatient or outpatient setting); and

(B)

non-opioid alternatives for the treatment of pain.

(2)

Challenges associated with such plans offering supplemental health care benefits relating to coverage of items and services described in subparagraph (A) or (B) of paragraph (1).

(3)

The impact, if any, increasing the applicable rebate percentage determined under section 1854(b)(1)(C) of the Social Security Act (42 U.S.C. 1395w–24(b)(1)(C)) for plans offering such benefits relating to such coverage would have on the availability of such benefits relating to such coverage offered under Medicare Advantage plans.

(4)

Potential ways to improve upon such coverage or to incentivize such plans to offer additional supplemental health care benefits relating to such coverage.